Previous 10 | Next 10 |
Finding optimum penny stocks can be tricky. There are literally thousands of options out there, but when you pick the right one, the investment can be highly rewarding. These lower-priced shares can be subject to sudden price changes with wide thresholds—this offers risk an...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) took a steep hit last week, crashing from 3,422.32 points on Monday’s (July 8) open to 3,315.46 points as of 1:32 p.m. EDT on Friday (July 12). A likely catalyst for the index’s crash was US President Donald Trump’s pled...
Dave & Buster's Entertainment (NASDAQ: PLAY ) -17% on Q1 earnings . More news on: Dave & Buster's Entertainment, Inc., ContraVir Pharmaceuticals, Inc., Seadrill Limited, Stocks on the move, Read more ...
LEXINGTON, Mass. , June 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a publication titled "U2AF1 mutations induce oncogenic IRAK4 isoforms and activate...
The global pharmaceutical market has been growing at a rapid rate in recent years and is expected to reach $1.57 trillion USD by 2023, signaling a major opportunity for investors to cash in on pharmaceutical stocks. Some of the factors behind the market’s growth include the ...
Curis, Inc. (CRIS) Q1 2019 Results Earnings Conference Call May 14, 2019, 04:30 PM ET Company Participants Bill Steinkrauss - VP, Finance James Dentzer - President and CEO Bob Martell - Head of R&D Conference Call Participants Presentation Operator Good afternoo...
Curis (NASDAQ: CRIS ): Q1 GAAP EPS of -$0.30. Revenue of $1.8M (-27.1% Y/Y) Press Release More news on: Curis, Inc., Earnings news and commentary, Healthcare stocks news, ,
LEXINGTON, Mass. , May 14, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019. "20...
LEXINGTON, Mass. , May 7, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 1...
LEXINGTON, Mass. , May 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesotheliom...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...